Track accepted paper

Journal Metrics

Source Normalized Impact per Paper (SNIP): 1.231ℹSource Normalized Impact per Paper (SNIP):2014: 1.231SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.

SCImago Journal Rank (SJR): 1.988ℹ

SCImago Journal Rank (SJR):2014: 1.988SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.

Stay up-to-date

Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).

Neuropharmacology also publishes succinct topical reviews on subjects within its remit. These reviews (of between 3000 and 5000 words) are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief ahead of time of their intention to submit a review and to indicate clearly how the review differs from, and adds to, recent published reviews on related topics. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a decision regarding their proposed review as quickly as possible.

The scope of the journal is broad. It covers many disciplines and spans molecules (e.g., molecular biology, biochemistry) through systems (e.g., neurophysiology) to behaviour (e.g. cognition, psychopharmacology). The journal covers all aspects of neuroscience with an emphasis on neurotransmitters and their receptors, ion channels, signalling, psychcopharmacology and animal models of disease, such as investigations on the neurobiology of cognition, depression, schizophrenia, anxiety, epilepsy, ischaemia, neuroprotection, neurodegeneration, drugs of abuse and pain.

The journal publishes occasional Special Issues (and will consider publishing Supplements). Each year Elsevier/Neuropharmacology organise a satellite symposium to the Meeting of the Society for Neuroscience. The journal publishes a Special Issue to accompany each meeting. Please see http://www.neuropharmacology-conference.elsevier.com/ for details of this year's meeting and accompanying Special Issue.

Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).

Neuropharmacology also publishes succinct topical reviews on subjects within its remit. These reviews (of between 3000 and 5000 words) are commissioned by the Editorial Team or arise after...

This application allows readers to explore NCBI data on author-tagged genes through an interactive genetic sequence viewer that supports flipping strands, zooming to a sequence, selecting a specific position, and more.

The colored bars illustrate the engagement of the social media communities with articles in Neuropharmacology. It is based on the amount of activity from Twitter, Facebook, science blogs, mainstream news, and other sources captured by Altmetric.com for each publication in the last six months. Let us know what you think about altmetrics.